← All trials
NCT05769868
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2023
- Primary completion
- Mar 31, 2027
- Completion date
- Sep 30, 2027
- First posted
- Mar 15, 2023
- Last posted
- May 1, 2023
- Enrollment
- 1000
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Consorcio Centro de Investigación Biomédica en Red, M.P.Lead sponsor
- Hospital General Universitario Gregorio MarañonOverall official - principal investigator
- Universidad Carlos III MadridCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.